TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01115725

Intervention type: DRUG
Intervention: Gonal-f® (follitropin alfa)
Description: Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
Study: NCT03259776

Intervention type: OTHER
Intervention: Qualitative interviews and questionnaire survey
Description: Qualitative interviews and questionnaire survey
Study: NCT02785029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT
Study: NCT03933137

Intervention type: OTHER
Intervention: Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score
Description: P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).

Intervention type: OTHER
Intervention: Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score
Description: P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
Study: NCT00732966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: with losartan 50 mg once daily for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: with losartan 50 mg once daily for one month
Study: NCT02697981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition counseling
Description: nutrition counseling and guidance.
Study: NCT01071252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Study: NCT00732966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: valsartan 160 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: valsartan 160 mg once daily
Study: NCT00090519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruboxistaurin
Description: 32 mg once daily (QD) oral for up to 36 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: QD oral for up to 36 months
Study: NCT02645942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine 1400 mg daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 8 weeks
Study: NCT00694889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroadaptive cognitive training
Description: Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
Study: NCT01071252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05023291

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Positron Emissie Tomografie - Computer Tomografie
Description: In this study, the high-resolution PET-CT system will be used to evaluate the cutting edges after tumor resection. The goal is to evaluate the distance of the tumor cells from the cutting edges of the surgical piece. The patient receives an intravenous injection of radiolabeled sugar (18F-FDG). 18F-FDG is the standard PET tracer for diagnostic PET-CT research. This standard dose will always be calculated according to the formula: 3.7 x body weight + 37 Mbq.
Study: NCT00204594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rM28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous PBMCs
Study: NCT03333252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Condition
Description: Caregivers will access caregiving related information. Care Recipients will access cognitive training program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
Study: NCT02793349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb Bioresorbable Vascular Scaffold
Description: Absorb Bioresorbable Vascular Scaffold
Study: NCT03621176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
Study: NCT04105348

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2

Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c
Description: patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
Study: NCT01551680

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation combined with iniparib (BSI-201)
Description: Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields.
Study: NCT02494518

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forced Exercise & Upper Extremity Repetitive Task Practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voluntary Exercise & Upper Extremity Repetitive Task Practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Education & Upper Extremity Repetitive Task Practice
Study: NCT01377155

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin detemir
Description: Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
Study: NCT02724917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APN1125
Description: Oral solid dose form of APN1125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APN1125
Description: Oral solid dose form of APN1125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APN1125
Description: Oral solid dose form of APN1125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match
Study: NCT02662504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy (PDT)
Description: Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic surgery Pleurectomy / extended Decortication
Description: extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
Study: NCT00144989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide and cisplatin after chemoradiotherapy
Description: Etoposide and cisplatin after chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and cisplatin after chemoradiotherapy
Description: Irinotecan and cisplatin after chemoradiotherapy
Study: NCT03178123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody Toripalimab
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: high-dose recombinant interferon a-2B
Description: 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15\*10\^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
Study: NCT03520348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-167
Description: Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corneregel
Description: Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
Study: NCT04367311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60-75 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60-75 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60-75 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500mg/m\^2
Study: NCT04807088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tactile-kinesthetic Stimulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05078515

Intervention type: DIAGNOSTIC_TEST
Intervention: PREDICT score
Description: Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: PREDICT score
Description: Predictive score for local recurrence after TME for rectal cancer that includes 8 parameters
Study: NCT00889603

Intervention type: DRUG
Intervention: Aricept® Evess
Description: 5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing).
Study: NCT03628066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg by mouth daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oncotype DX Breast Recurrence Score
Description: Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
Study: NCT04523623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: oxycodone 0.2mg/kg, max 10mg to be administered, randomized between that and Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 10mg/kg, max 800mg, randomized between that and Oxycodone
Study: NCT00694889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuroadaptive cognitive training
Description: Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
Study: NCT03758352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (rIC)
Description: Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.

Intervention type: OTHER
Group type: OTHER
Intervention: non remote ischemic preconditioning (non-rIC)
Description: Retrospective group who have not undergone intervention.
Study: NCT03672747

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct-current stimulation (tDCS)
Description: 20 minutes duration using high-definition system with center-surround configuration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct-current stimulation (tDCS)
Description: 20 minutes duration using high-definition system with center-surround configuration

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct-current stimulation (tDCS)
Description: 20 minutes duration using high-definition system with center-surround configuration
Study: NCT04236830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride/ potassium iodide
Description: Thirty six first permanent molars will receive 38% SDF/KI as an indirect pulp capping material.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Thirty six first permanent molars will receive 38% SDF as an indirect pulp capping material.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin modified glass ionomer cement
Description: Thirty six first permanent molars will receive RMGIC as an indirect pulp capping material.
Study: NCT03478267

Intervention type: DIAGNOSTIC_TEST
Intervention: AChE levels
Description: AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.

Intervention type: DIAGNOSTIC_TEST
Intervention: AChE levels
Description: AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
Study: NCT00563979

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VitaluxPlus®
Description: 1 tablet daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Description: 1 tablet daily
Study: NCT01918085

Intervention type: OTHER
Group type: OTHER
Intervention: Hydrocolloid strip
Description: An adhesive strip made of hydrocolloid adhesive

Intervention type: OTHER
Group type: OTHER
Intervention: Hydrocolloid strip
Description: An adhesive strip made of hydrocolloid adhesive

Intervention type: OTHER
Group type: OTHER
Intervention: Strata strip
Description: An adhesive strip made of the Strata adhesive
Study: NCT01813058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~1. placebo i.e. saline 0.9% (intravenous injection)~2. intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~1. Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~2. TXA as previously described.
Study: NCT00675441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
Study: NCT02021383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bi-weekly in person meetings with a Registered Dietician
Description: Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives for weight loss maintenance
Description: Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives for weight loss maintenance
Description: Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
Study: NCT03853382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive analytic informed brief therapy
Description: The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings.
Study: NCT00170768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily tablet (sham titration)
Study: NCT02824770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dimming of lights and decreasing noise level
Description: The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine (Bustesin®) via Pain Buster ® system
Description: Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Bustesin®) via Pain Buster ® system
Description: Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl (Tramosel®) via PCA system (Gemstar®)
Description: Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
Study: NCT01918085

Intervention type: OTHER
Group type: OTHER
Intervention: Strata strip
Description: An adhesive strip made of the Strata adhesive
Study: NCT03252834

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI
Description: Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI
Description: Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
Study: NCT00467571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole, clarithromycin, amoxycillin
Description: lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days